TPN171H ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
86 | 肺動脈性肺高血圧症 | 2 |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05208814 (ClinicalTrials.gov) | February 28, 2022 | 29/12/2021 | a Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients With Renal Insufficiency and Healthy Subjects | a Parallel, Open, Single-dose Administration Phase I Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients With Renal Insufficiency and Healthy Subjects | Pulmonary Arterial Hypertension;Erectile Dysfunction | Drug: TPN171H single dose | Vigonvita Life Sciences | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Not yet recruiting | 18 Years | 70 Years | All | 56 | Phase 1 | NULL |
2 | NCT04483115 (ClinicalTrials.gov) | November 16, 2020 | 15/7/2020 | Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension | Multi-center, Randomized,Placebo and Positive Controlled Clinical Study of TPN171H Tablets on Acute Haemodynamics in Patients With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: TPN171H;Drug: Placebo;Drug: Tadalafil | Vigonvita Life Sciences | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | China |